Renin-Angiotensin System (RAS) is involved with hypertension and other cardiovascular diseases. However, the association of RAS components to cancer still causes suspicion. To try to clarify this, here we aimed to show this association for three important components: Angiotensin Converting Enzyme 1 (ACE1), Angiotensin Type 1 Receptor (AGTR1) and Angiotensin Type 2 Receptor (AGTR2). The first articles show that association of RAS components with cancer dates back to the 70’s. ECA1 and AGTR1 have close association with cancer and ACE1 inhibitors or AGTR1 blockers are candidates to treatment of some tumors. Moreover, the action of AGTR2 is still controversial, but most studies show that the increased expression of AGTR2 can attack the cancer cells. In breast cancer, these components have also been widely studied and many works have shown that the correlation exists. Therefore specific target using these RAS components could be a beneficial, novel therapy to various tumors.
References
[1]
de Gasparo, M., Catt, K.J., Inagami, T., Wright, J.W. and Unger, T. (2000) International Union of Pharmacology, XXIII. The Angiotensin II Receptors. Pharmacological Reviews, 52, 415-472.
[2]
Kaschina, E. and Unger, T. (2003) Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function. Blood Pressure, 12, 70-88. http://dx.doi.org/10.1080/08037050310001057
[3]
Sugimoto, M., Yamaoka, Y., Shirai, N. and Furuta, T. (2012) Role of Reninangiotensin System in Gastric Oncogenesis. Journal of Gastroenterology and Hepatology, 27, 442-451. http://dx.doi.org/10.1111/j.1440-1746.2011.06964.x
[4]
Vinson, G.P., Barker, S., Puddefoot, J.R. and Tahmasebi, M. (2007) The Rennin-Angiotensin System in the Breast. In: Leung, P.S., Ed., Frontiers in Research of the Renin-Angiotensin System on Human Disease, Springer, Netherlands, 135-153.
[5]
Ptasińska-Wnuk, D., Lawnicka, H., Fryczak, J., Kunert-Radek, J. and Pawlikowski, M. (2007) Angiotensin Peptides Regulate Angiogenic Activity in Rat Anterior Pituitary Tumour Cell Cultures. Endokrynologia Polska, 58, 478-486.
[6]
de Ronde, J.J., Lips, E.H., Mulder, L., Vincent, A.D., Wesseling, J., Nieuwland, M., Kerkhoven, R., Vrancken Peeters, M.J., Sonke, G.S., Rodenhuis, S. and Wessels, L.F. (2013) SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B Are Markers of Resistance to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer. Breast Cancer Research and Treatment, 137, 213-223. http://dx.doi.org/10.1007/s10549-012-2340-x
[7]
De Paepe, B., Verstraeten, V.M., De Potter, C.R. and Bullock, G.R. (2002) Increased Angiotensin II Type-2 Receptor Density in Hyperplasia, DCIS and Invasive Carcinoma of the Breast Is Paralleled with Increased iNOS Expression. Histochemistry and Cell Biology, 117, 13-19. http://dx.doi.org/10.1007/s00418-001-0356-0
[8]
Tahmasebi, M., Barker, S., Puddefoot, J.R. and Vinson, G.P. (2006) Localisation of Renin-Angiotensin System (RAS) Components in Breast. British Journal of Cancer, 95, 67-74. http://dx.doi.org/10.1038/sj.bjc.6603213
[9]
Leckie, B., Brown, J.J., Fraser, R., Kyle, K., Lever, A.F., Morton, J.J. and Robertson, J.I. (1978) A Renal Carcinoma Secreting Inactive Renin. Clinical science and Molecular Medicine Supplement, 4, 159s-161s. http://dx.doi.org/10.1042/cs055159s
[10]
Romer, F.K. (1981) Angiotensin-Converting Enzyme and Its Association with Outcome in Lung Cancer. British Journal of Cancer, 43, 135-142. http://dx.doi.org/10.1038/bjc.1981.21
[11]
Takahashi, N., Kunii, Y., Kanno, H. and Kikuchi, K. (1982) Clinical Studies of Cancer Chemotherapy Combined with Angiotensin-II (ANG-II). Gan to Kagaku Ryoho, 9, 1640-1645.
[12]
Koyama, H., Nishizawa, Y., Wada, T., Sasaki, Y., Terasawa, T., Hasegawa, Y. and Nakano, S. (1983) Effects of Angiotensin-Induced Hypertension on Cancer Chemotherapy. Application to Intra-Arterial Infusion Chemotherapy for Advanced Breast Cancer. Gan to Kagaku Ryoho, 10, 1584-1590.
[13]
Mizuno, K., Ojima, M., Hashimoto, S. and Fukuchi, S. (1985) Renin and Angiotensin-Converting Enzyme in Human Neuroblastoma Tissue. Journal of Neurochemistry, 45, 626-629. http://dx.doi.org/10.1111/j.1471-4159.1985.tb04032.x
[14]
Konishi, T., Kitamura, M., Suzuki, T., Mori, T., Awane, Y. and Kosaki, G. (1985) Intra-Arterial Infusion Therapy with Angiotensin II in Gastric Carcinoma. Gan to Kagaku Ryoho, 12, 1905-1914.
[15]
Mc Menamin, ú.C., Murray, L.J., Cantwell, M.M. and Hughes, C.M. (2012) Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Cancer Progression and Survival: A Systematic Review. Cancer Causes Control, 23, 221-230. http://dx.doi.org/10.1007/s10552-011-9881-x
[16]
Puddefoot, J.R., Udeozo, U.K., Barker, S. and Vinson, G.P. (2006) The Role of Angiotensin II in the Regulation of Breast Cancer Cell Adhesion and Invasion. Endocrine-Related Cancer, 13, 895-903.
[17]
Shin, A., Cai, Q., Shu, X.O., Gao, Y.T. and Zheng, W. (2005) Genetic Polymorphisms in the Matrix Metalloproteinase 12 Gene (MMP12) and Breast Cancer Risk and Survival: The Shanghai Breast Cancer Study. Breast Cancer Research, 7, R506-R512. http://dx.doi.org/10.1186/bcr1033
[18]
Inwang, E.R., Puddefoot, J.R., Brown, C.L., Goode, A.W., Marsigliante, S., Ho, M.M., Payne, J.G. and Vinson, G.P. (1997) Angiotensin II Type 1 Receptor Expression in Human Breast Tissues. British Journal of Cancer, 75, 1279-1283. http://dx.doi.org/10.1038/bjc.1997.217
[19]
George, A.J., Thomas, W.G. and Hannan, R.D. (2010) The Renin-Angiotensin System and Cancer: Old Dog, New Tricks. Nature Reviews Cancer, 10, 745-759. http://dx.doi.org/10.1038/nrc2945
[20]
Mendizábal-Ruiz, A.P., Morales, J., Castro Martinez, X., Gutierrez Rubio, S.A., Valdez, L., Vásquez-Camacho, J.G., Sanchez Corona, J. and Moran Moguel, M.C. (2011) RAS Polymorphisms in Cancerous and Benign Breast Tissue. Journal of Renin-Angiotensin-Aldosterone, 12, 85-92. http://dx.doi.org/10.1177/1470320310383735
[21]
Namazi, S., Monabati, A., Ardeshir-Rouhani-Fard, S. and Azarpira, N. (2010) Association of Angiotensin I Converting Enzyme (Insertion/Deletion) and Angiotensin II Type 1 Receptor (A1166C) Polymorphisms with Breast Cancer Prognostic Factors in Iranian Population. Molecular Carcinogenesis, 49, 1022-1030. http://dx.doi.org/10.1002/mc.20685
[22]
Zhang, Y., He, J., Deng, Y., Zhang, J., Li, X., Xiang, Z., Huang, H., Tian, C., Huang, J. and Fan, H. (2011) The Insertion/Deletion (I/D) Polymorphism in the Angiotensin-Converting Enzyme Gene and Cancer Risk: A Meta-Analysis. BMC Medical Genetics, 12, 159. http://dx.doi.org/10.1186/1471-2350-12-159
[23]
Ateeq, B., Tomlins, S.A. and Chinnaiyan, A.M. (2009) AGTR1 as a Therapeutic Target in ER-Positive and ERBB2-Negative Breast Cancer Cases. Cell Cycle, 8, 3794-3795. http://dx.doi.org/10.4161/cc.8.23.9976
[24]
Alves Corrêa, S.A., Ribeiro de Noronha, S.M., Nogueira-de-Souza, N.C., Valleta de Carvalho, C., Massad Costa, A.M., Juvenal Linhares, J., Vieira Gomes, M.T. and Guerreiro da Silva, I.D. (2009) Association between the Angiotensin-Converting Enzyme (Insertion/Deletion) and Angiotensin II Type 1 Receptor (A1166C) Polymorphisms and Breast Cancer among Brazilian Women. Journal of Renin-Angiotensin-Aldosterone, 10, 51-58. http://dx.doi.org/10.1177/1470320309102317
[25]
Zhao, Y., Chen, X., Cai, L., Yang, Y., Sui, G. and Wu, J. (2008) Angiotensin II Suppresses Adriamycin-Induced Apoptosis through Activation of Phosphatidylinositol 3-Kinase/Akt Signaling in Human Breast Cancer Cells. Acta Biochimica et Biophysica Sinica (Shanghai), 40, 304-310. http://dx.doi.org/10.1111/j.1745-7270.2008.00402.x
[26]
van der Knaap, R., Siemes, C., Coebergh, J.-W., van Duijn, C.M., Hofman, A. and Stricker, B.H. (2008) Renin-Angiotensin System Inhibitors, Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism, and Cancer: The Rotterdam Study. Cancer, 112, 748-757. http://dx.doi.org/10.1002/cncr.23215
[27]
Yaren, A., Turgut, S., Kursunluoglu, R., Oztop, I., Turgut, G., Degirmencioglu, S., Kelten, C. and Erdem, E. (2007) Insertion/Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene in Patients with Breast Cancer and Effects on Prognostic Factors. Journal of Investigative Medicine, 55, 255-261.
[28]
Haiman, C.A., Henderson, S.O., Bretsky, P., Kolonel, L.N. and Henderson, B.E. (2003) Genetic Variation in Angiotensin I-Converting Enzyme (ACE) and Breast Cancer Risk: The Multiethnic Cohort. Cancer Research, 63, 6984-6987.
[29]
Muscella, A., Greco, S., Elia, M.G., Storelli, C. and Marsigliante, S. (2002) Angiotensin II Stimulation of Na+/K+ ATPase Activity and Cell Growth by Calcium-Independent Pathway in MCF-7 Breast Cancer Cells. Journal of Endocrinology, 173, 315-323. http://dx.doi.org/10.1677/joe.0.1730315
[30]
De Paepe, B., Verstraeten, V.L., De Potter, C.R., Vakaet, L.A. and Bullock, G.R. (2001) Growth Stimulatory Angiotensin II Type-1 Receptor Is Upregulated in Breast Hyperplasia and in Situ Carcinoma but Not in Invasive Carcinoma. Histochemistry and Cell Biology, 116, 247-254. http://dx.doi.org/10.1007/s004180100313
[31]
Meier, C.R., Derby, L.E., Jick, S.S. and Jick, H. (2000) Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, and Breast Cancer. Archives of Internal Medicine, 160, 349-353. http://dx.doi.org/10.1001/archinte.160.3.349
[32]
Small Jr., W., Molteni, A., Kim, Y.T., Taylor, J.M., Ts’ao, C.-H. and Ward, W.F. (1999) Mechanism of Captopril Toxicity to a Human Mammary Ductal Carcinoma Cell Line in the Presence of Copper. Breast Cancer Research and Treatment, 55, 223-229. http://dx.doi.org/10.1023/A:1006233521325
[33]
Tahmasebi, M., Puddefoot, J.R., Inwang, E.R., Goode, A.W., Carpenter, R. and Vinson, G.P. (1998) Transcription of the Prorenin Gene in Normal and Diseased Breast. European Journal of Cancer, 34, 1777-1782. http://dx.doi.org/10.1016/S0959-8049(98)00173-7
[34]
Fishchuk, L.E. and Gorovenko, N.G. (2013) Genetic Polymorphisms of the Renin-Angiotensin System in Breast Cancer Patients. Experimental Oncology, 35, 101-104.
[35]
Ladd, A.M., Vasquez, A.A., Siemes, C., Yazdanpanah, M., Coebergh, J.W., Hofman, A., Stricker, B.H. and van Duijn, C.M. (2007) Differential Roles of Angiotensinogen and Angiotensin Receptor Type 1 Polymorphisms in Breast Cancer Risk. Breast Cancer Research and Treatment, 101, 299-304. http://dx.doi.org/10.1007/s10549-006-9290-0
[36]
Correa-Noronha, S.A., Ribeiro de Noronha, S.M., Alecrim, C., Mesquita, A.D., Brito, G.S., Junqueira, M.G., Leite, D.B., Carvalho, C.V. and Silva, I.D. (2012) Association of Angiotensin-Converting Enzyme I Gene I/D Polymorphism with Endometrial but Not with Ovarian Cancer. Gynecological Endocrinology, 28, 889-891. http://dx.doi.org/10.3109/09513590.2012.683060
[37]
Song, L., Zhang, S.L., Bai, K.H., Yang, J., Xiong, H.Y., Li, X., Liu, T. and Liu, H.R. (2013) Serum Agonistic Autoantibodies against Type-1 Angiotensin II Receptor Titer in Patients with Epithelial Ovarian Cancer: A Potential Role in Tumor Cell Migration and Angiogenesis. Journal of Ovarian Research, 6, 22. http://dx.doi.org/10.1186/1757-2215-6-22
[38]
Qian, Y.R., Guo, Y., Wan, H.Y., Fan, L., Feng, Y., Ni, L., Xiang, Y. and Li, Q.Y. (2013) Angiotensin-Converting Enzyme 2 Attenuates the Metastasis of Non-Small Cell Lung Cancer through Inhibition of Epithelial-Mesenchymal Transition. Oncology Reports, 29, 2408-2414.
[39]
Rinsho, N. (2012) [Renin-Angiotensin System (RAS) as New Molecular Therapeutic Targets in Prostate Cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 70, 1604-1612.
[40]
Kuniyasu, H. (2012) Multiple Roles of Angiotensin in Colorectal Cancer. World Journal of Clinical Oncology, 3, 150-154.
[41]
Yuge, K., Miyajima, A., Tanaka, N., Shirotake, S., Kosaka, T., Kikuchi, E. and Oya, M. (2012) Prognostic Value of Renin-Angiotensin System Blockade in Non-Muscle-Invasive Bladder Cancer. Annals of Surgical Oncology, 19, 3987- 3993. http://dx.doi.org/10.1245/s10434-012-2568-z
[42]
Stoll, M. and Unger, T. (2001) Angiotensin and Its AT2 Receptor: New Insights into an Old System. Regulatory Peptides, 99, 175-182. http://dx.doi.org/10.1016/s0167-0115(01)00246-4
[43]
Thomas, W.G. and Mendelsohn, F.A.O. (2003) Molecules in Focus Angiotensin Receptors: Form and Function and Distribution. The International Journal of Biochemistry & Cell Biology, 35, 774-779. http://dx.doi.org/10.1016/S1357-2725(02)00263-7
[44]
Wen, S.W., Ager, E.I., Neo, J. and Christophi, C. (2013) The Renin Angiotensin System Regulates Kupffer Cells in Colorectal Liver Metastases. Cancer Biology & Therapy, 14, 720-727. http://dx.doi.org/10.4161/cbt.25092
[45]
Liu, Y.T., Lin, L.W., Chen, C.Y., Wang, C.P., Liu, H.P., Houng, J.Y., Chung, F.M. and Shieh, T.Y. (2012) Polymorphism of Angiotensin I-Converting Enzyme Gene Is Related to Oral Cancer and Lymph Node Metastasis in Male Betel Quid Chewers. Oral Oncology, 48, 1257-1262. http://dx.doi.org/10.1016/j.oraloncology.2012.06.003
[46]
Yuan, F., Zhang, L.-S., Li, H.-Y., Liao, M., Lv, M. and Zhang, C. (2013) Influence of Angiotensin I-Converting Enzyme Gene Polymorphism on Hepatocellular Carcinoma Risk in China. DNA and Cell Biology, 32, 268-273. http://dx.doi.org/10.1089/dna.2012.1910
[47]
Albayrak, M., Celebi, H., Albayrak, A., Sayilir, A., Yesil, Y., Balcik, O.S., Yokus, O. and Celik, T. (2012) Elevated Serum Angiotensin Converting Enzyme Levels as a Reflection of Bone Marrow Renin-Angiotensin System Activation in Multiple Myeloma. Journal of Renin-Angiotensin-Aldosterone, 13, 259-264. http://dx.doi.org/10.1177/1470320312437070
[48]
Devic Pavlic, S., Ristic, S., Flego, V., Kapovic, M. and Radojcic Badovinac, A. (2012) Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism in Lung Cancer Patients. Genetic Testing and Molecular Biomarkers, 16, 722-725. http://dx.doi.org/10.1089/gtmb.2011.0306
[49]
Chae, Y.K., Brown, E.N., Lei, X., Melhem-Bertrandt, A., Giordano, S.H., Litton, J.K., Hortobagyi, G.N., Gonzalez-Angulo, A.M. and Chavez-Macgregor, M. (2013) Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. Journal of Cancer, 4, 549-556. http://dx.doi.org/10.7150/jca.6888
[50]
Uemura, H. and Kubota, Y. (2009) [Role of Renin-Angiotensin System in Prostate Cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy, 36, 1228-1233.
[51]
Da, Y.J., Yuan, W.D., Zhu, L.F. and Chen, Z.L. (2012) Synthesis, Anti-Hypertensive Effect of a Novel Angiotensin II AT1 Receptor Antagonist and Its Anti-Tumor Activity in Prostate Cancer. Arzneimittelforschung, 62, 637-643. http://dx.doi.org/10.1055/s-0032-1329952
[52]
Fujita, M., Hayashi, I., Yamashina, S., Itoman, M. and Majima, M. (2002) Blockade of Angiotensin AT1a Receptor Signaling Reduces Tumor Growth, Angiogenesis, and Metastasis. Biochemical and Biophysical Research Communications, 294, 441-447. http://dx.doi.org/10.1016/S0006-291X(02)00496-5
[53]
Piastowska-Ciesielska, A.W., Pluciennik, E., Wójcik-Krowiranda, K., Bieńkiewicz, A., Nowakowska, M., Pospiech, K., Bednarek, A.K., Domińska, K. and Ochedalski, T. (2013) Correlation between VEGFR-2 Receptor Kinase Domain-Containing Receptor (KDR) mRNA and Angiotensin II Receptor Type 1 (AT1-R) mRNA in Endometrial Cancer. Cytokine, 61, 639-644. http://dx.doi.org/10.1016/j.cyto.2012.11.017
[54]
Amano, H., Ito, Y., Ogawa, F., Eshima, K., Suzuki, T., Oba, K., Matsui, Y., Kato, S., Fukui, T., Nakamura, M., Kitasato, H., Fukamizu, A. and Majima, M. (2013) Angiotensin II Type 1A Receptor Signaling Facilitates Tumor Metastasis Formation through P-Selectin-Mediated Interaction of Tumor Cells with Platelets and Endothelial Cells. American Journal of Pathology, 182, 553-564. http://dx.doi.org/10.1016/j.ajpath.2012.10.026
[55]
Uemura, H. and Kubota, Y. (2012) [Cancer and Renin-Angiotensin System]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 70, 1530-1535.
[56]
Domińska, K., Piastowska-Ciesielska, A.W., Lachowicz-Ochedalska, A. and Ochedalski, T. (2012) Similarities and Differences between Effects of Angiotensin III and Angiotensin II on Human Prostate Cancercell Migration and Proliferation. Peptides, 37, 200-206. http://dx.doi.org/10.1016/j.peptides.2012.07.022
[57]
Uemura, H., Hoshino, K. and Kubota, Y. (2011) Engagement of Renin-Angiotensin System in Prostate Cancer. Current Cancer Drug Targets, 11, 442-450. http://dx.doi.org/10.2174/156800911795538101
[58]
Akhavan, M.M., Karimi, M., Ghodrati, M. and Falahtpishe, H. (2011) AT1 Receptors Activation Enhances the Expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 Melanoma Cells. Pakistan Journal of Biological Sciences, 14, 821-830. http://dx.doi.org/10.3923/pjbs.2011.821.830
[59]
Pérez-Díaz, I., Guzmán, C., Olivares-Reyes, J.A., Ramírez, T., Gutierréz-Reyes, G., Hiriart, M. and Robles-Díaz, G. (2011) Evidence of an Intracellular Angiotensin-Generating System and Non-AT1, Non-AT2 Binding Site in a Human Pancreatic Cell Line. Pancreas, 40, 701-707. http://dx.doi.org/10.1097/MPA.0b013e318215a891
[60]
Peng, M.Y., Wang, L.L., Liang, T., Zhao, X.L., Wang, G.P. and Chen, F.P. (2010) Expression of Angiotensin-II Type 1 Receptor AT1 mRNA in Myeloid Leukemia. Journal of Experimental Hematology, 18, 1418-1421.
[61]
Clere, N., Corre, I., Faure, S., Guihot, A.L., Vessières, E., Chalopin, M., Morel, A., Coqueret, O., Hein, L., Delneste, Y., Paris, F. and Henrion, D. (2010) Deficiency or Blockade of Angiotensin II Type 2 Receptor Delays Tumorigenesis by Inhibiting Malignant Cell Proliferation and Angiogenesis. International Journal of Cancer, 127, 2279-2291. http://dx.doi.org/10.1002/ijc.25234
[62]
Guimond, M.O., Battista, M.C., Nikjouitavabi, F., Carmel, M., Barres, V., Doueik, A.A., Fazli, L., Gleave, M., Sabbagh, R. and Gallo-Payet, N. (2013) Expression and Role of the Angiotensin II AT2 Receptor in Human Prostate Tissue: In Search of a New Therapeutic Option for Prostate Cancer. The Prostate, 73, 1057-1068. http://dx.doi.org/10.1002/pros.22653
[63]
Kawabata, A., Baoum, A., Ohta, N., Jacquez, S., Seo, G.M., Berkland, C. and Tamura, M. (2012) Intratracheal Administration of a Nanoparticle-Based Therapy with the Angiotensin II Type 2 Receptor Gene Attenuates Lung Cancer Growth. Cancer Research, 72, 2057-2067. http://dx.doi.org/10.1158/0008-5472.CAN-11-3634
[64]
Dolley-Hitze, T., Jouan, F., Martin, B., Mottier, S., Edeline, J., Moranne, O., Le Pogamp, P., Belaud-Rotureau, M.A., Patard, J.J., Rioux-Leclercq, N. and Vigneau, C. (2010) Angiotensin-2 Receptors (AT1-R and AT2-R), New Prognostic Factors for Renal Clear-Cell Carcinoma? British Journal of Cancer, 103, 1698-1705. http://dx.doi.org/10.1038/sj.bjc.6605866
[65]
Doi, C., Egashira, N., Kawabata, A., Maurya, D.K., Ohta, N., Uppalapati, D., Ayuzawa, R., Pickel, L., Isayama, Y., Troyer, D., Takekoshi, S. and Tamura, M. (2010) Angiotensin II Type 2 Receptor Signaling Significantly Attenuates Growth of Murine Pancreatic Carcinoma Grafts in Syngeneic Mice. BMC Cancer, 10, 67. http://dx.doi.org/10.1186/1471-2407-10-67
[66]
Li, H., Qi, Y., Li, C., Braseth, L.N., Gao, Y., Shabashvili, A.E., Katovich, M.J. and Sumners, C. (2009) Angiotensin Type 2 Receptor-Mediated Apoptosis of Human Prostate Cancer Cells. Molecular Cancer Therapeutics, 8, 3255-3265. http://dx.doi.org/10.1158/1535-7163.MCT-09-0237
[67]
Pickel, L., Matsuzuka, T., Doi, C., Ayuzawa, R., Maurya, D.K., Xie, S.X., Berkland, C. and Tamura, M. (2010) Over- Expression of Angiotensin II Type 2 Receptor Gene Induces Cell Death in Lung Adenocarcinoma Cells. Cancer Biology & Therapy, 9, 277-285. http://dx.doi.org/10.4161/cbt.9.4.10643
[68]
Matsumoto, T., Sagawa, N., Mukoyama, M., Tanaka, I., Itoh, H., Goto, M., Itoh, H., Horiuchi, M., Dzau, V.J., Mori, T. and Nakao, K. (1996) Type 2 Angiotensin II Receptor Is Expressed in Human Myometrium and Uterine Leiomyoma and Is Down-Regulated during Pregnancy. The Journal of Clinical Endocrinology and Metabolism, 81, 4366-4372.
[69]
Wolgien, M.C.G.M., Silva, I.D.C.G., Nazário, A.C.F., Nakaie, C.R., Noronha, S.A.A.C., Ribeiro de Noronha, S.M. and Facina, G. (2013) Plasma Levels of Angiotensin-Converting Enzymes 1 and 2 and AGTR2 (T1247G and A5235G) Gene Polymorphisms Are Associated to Breast Cancer Progression. Journal of Cancer Therapy, 4, 1403-1410. http://dx.doi.org/10.4236/jct.2013.49167
[70]
Noronha, S.A.A.C., Bernardo,W., Barros, A.J., Nakaie, C.R., Shimuta, S.I., Silva, I.D.C.G. and Noronha, S.M.R. (2013) Effects on Cell Viability and on Apoptosis in Tumoral (MCF-7) and in Normal (MCF10A) Epithelial Breast Cells after Human Chorionic Gonadotropin and Derivated-Angiotensin Peptides Treatments. Journal of Cancer Therapy, 4, 65-69. http://dx.doi.org/10.4236/jct.2013.47A010
[71]
Binda Neto, I., Noronha, S.M.R., Noronha, S.A.A.C., Wolgien, M.D.C. M., Barros, A.J., Nakaie, C.R., Shimuta, S.I., Facina, G. and Silva, I.D.C.G. (2013) Angiotensin-(1 - 7) and Human Chorionic Gonadotropin (hCG) Modulate the Nuclear Transcription Factors or Nuclear Receptors Genes in the Tumorigenic Undifferentiated Breast Cancer Cell Line SKBR3. Journal of Cancer Therapy, 4, 70-74. http://dx.doi.org/10.4236/jct.2013.47A011
[72]
Jethon, A., Pula, B., Piotrowska, A., Wojnar, A., Rys, J., Dziegiel, P. and Podhorska-Okolow, M. (2012) Angiotensin II Type 1 Receptor (AT-1R) Expression Correlates with VEGF-A and VEGF-D Expression in Invasive Ductal Breast Cancer. Pathology & Oncology Research, 18, 867-873. http://dx.doi.org/10.1007/s12253-012-9516-x
[73]
Du, N., Feng, J., Hu, L.J., Sun, X., Sun, H.B., Zhao, Y., Yang, Y.P. and Ren, H. (2012) Angiotensin II Receptor Type 1 Blockers Suppress the Cell Proliferation Effects of Angiotensin II in Breast Cancer Cells by Inhibiting AT1R Signaling. Oncology Reports, 27, 1893-1903.
[74]
Tursz, T., Andre, F., Lazar, V., Lacroix, L. and Soria, J.C. (2011) Implications of Personalized Medicine—Perspective from a Cancer Center. Nature Reviews Clinical Oncology, 8, 177-183. http://dx.doi.org/10.1038/nrclinonc.2010.222
[75]
Rodrigues-Ferreira, S., Abdelkarim, M., Dillenburg-Pilla, P., Luissint, A.C., di-Tommaso, A., Deshayes, F., Pontes, C.L., Molina, A., Cagnard, N., Letourneur, F., Morel, M., Reis, R.I., Casarini, D.E., Terris, B., Couraud, P.O., Costa-Neto, C.M., Di, Benedetto, M. and Nahmias, C. (2012) Angiotensin II Facilitates Breast Cancer Cell Migration and Metastasis. PLoS ONE, 7, e35667. http://dx.doi.org/10.1371/journal.pone.0035667
